The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

AG-L-24521     (3R,4S,5R,6R,7R,9R,11R,12R,13S ,14R)-6-(4...

Synonyms: ANW-41694, SureCN12759047, CHEBI:136451, AC1L1HJO, CTK8B3052, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of clarithromycin

 

Psychiatry related information on clarithromycin

 

High impact information on clarithromycin

 

Chemical compound and disease context of clarithromycin

 

Biological context of clarithromycin

 

Anatomical context of clarithromycin

 

Associations of clarithromycin with other chemical compounds

 

Gene context of clarithromycin

 

Analytical, diagnostic and therapeutic context of clarithromycin

References

  1. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. Pierce, M., Crampton, S., Henry, D., Heifets, L., LaMarca, A., Montecalvo, M., Wormser, G.P., Jablonowski, H., Jemsek, J., Cynamon, M., Yangco, B.G., Notario, G., Craft, J.C. N. Engl. J. Med. (1996) [Pubmed]
  2. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. Talley, N.J., Vakil, N., Ballard, E.D., Fennerty, M.B. N. Engl. J. Med. (1999) [Pubmed]
  3. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. Shafran, S.D., Deschênes, J., Miller, M., Phillips, P., Toma, E. N. Engl. J. Med. (1994) [Pubmed]
  4. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Abbott, G.W., Sesti, F., Splawski, I., Buck, M.E., Lehmann, M.H., Timothy, K.W., Keating, M.T., Goldstein, S.A. Cell (1999) [Pubmed]
  5. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. Holmberg, S.D., Moorman, A.C., Von Bargen, J.C., Palella, F.J., Loveless, M.O., Ward, D.J., Navin, T.R. JAMA (1998) [Pubmed]
  6. The chemotherapeutic effects of H+/K+ inhibitors on Helicobacter pylori infection. Logan, R.P. Pharmacol. Ther. (1996) [Pubmed]
  7. Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis. Steinman, M.A., Steinman, T.I. Am. J. Kidney Dis. (1996) [Pubmed]
  8. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Wong, W.M., Gu, Q., Lam, S.K., Fung, F.M., Lai, K.C., Hu, W.H., Yee, Y.K., Chan, C.K., Xia, H.H., Yuen, M.F., Wong, B.C. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  9. Gastroprotective effect of intragastric clarithromycin against damage induced by ethanol in rats. Gutiérrez-Cabano, C.A., Raynald, A.C. Dig. Dis. Sci. (1999) [Pubmed]
  10. Relation between alcohol consumption and the success of Helicobacter pylori eradication therapy using omeprazole, clarithromycin and amoxicillin for 1 week. Baena, J.M., López, C., Hidalgo, A., Rams, F., Jiménez, S., García, M., Hernández, M.R. European journal of gastroenterology & hepatology. (2002) [Pubmed]
  11. A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. Nagaya, T., Fujieda, M., Otsuka, G., Yang, J.P., Okamoto, T., Seo, H. J. Clin. Invest. (2000) [Pubmed]
  12. Clarithromycin for atypical mycobacterial lymphadenitis in non-immunocompromised children. Tessier, M.H., Amoric, J.C., Méchinaud, F., Dubesset, D., Litoux, P., Stalder, J.F. Lancet (1994) [Pubmed]
  13. Clarithromycin and pseudomembranous enterocolitis. Braegger, C.P., Nadal, D. Lancet (1994) [Pubmed]
  14. Pancreatitis induced by clarithromycin. Liviu, L., Yair, L., Yehuda, S. Ann. Intern. Med. (1996) [Pubmed]
  15. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Osato, M.S., Reddy, R., Reddy, S.G., Penland, R.L., Malaty, H.M., Graham, D.Y. Arch. Intern. Med. (2001) [Pubmed]
  16. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Logan, R.P., Gummett, P.A., Schaufelberger, H.D., Greaves, R.R., Mendelson, G.M., Walker, M.M., Thomas, P.H., Baron, J.H., Misiewicz, J.J. Gut (1994) [Pubmed]
  17. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Bardhan, K.D., Dallaire, C., Eisold, H., Duggan, A.E. Gut (1997) [Pubmed]
  18. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Masiá, M., Gutiérrez, F., Jimeno, A., Navarro, A., Borrás, J., Matarredona, J., Martín-Hidalgo, A. Arch. Intern. Med. (2002) [Pubmed]
  19. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure. Matsuoka, M., Yoshida, Y., Hayakawa, K., Fukuchi, S., Sugano, K. Gut (1999) [Pubmed]
  20. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Trebesius, K., Panthel, K., Strobel, S., Vogt, K., Faller, G., Kirchner, T., Kist, M., Heesemann, J., Haas, R. Gut (2000) [Pubmed]
  21. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Dautzenberg, B., Saint Marc, T., Meyohas, M.C., Eliaszewitch, M., Haniez, F., Rogues, A.M., De Wit, S., Cotte, L., Chauvin, J.P., Grosset, J. Arch. Intern. Med. (1993) [Pubmed]
  22. Clinical implications of the immunomodulatory effects of macrolides. Tamaoki, J., Kadota, J., Takizawa, H. Am. J. Med. (2004) [Pubmed]
  23. Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance. Tomioka, H., Sano, C., Sato, K., Ogasawara, K., Akaki, T., Sano, K., Cai, S.S., Shimizu, T. J. Immunol. (2005) [Pubmed]
  24. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Wallace, R.J., Brown, B.A., Griffith, D.E., Girard, W.M., Murphy, D.T., Onyi, G.O., Steingrube, V.A., Mazurek, G.H. Am. J. Respir. Crit. Care Med. (1994) [Pubmed]
  25. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection. Yanagihara, K., Tomono, K., Sawai, T., Hirakata, Y., Kadota, J., Koga, H., Tashiro, T., Kohno, S. Am. J. Respir. Crit. Care Med. (1997) [Pubmed]
  26. Effect of Macrolides on In Vivo Ion Transport across Cystic Fibrosis Nasal Epithelium. Barker, P.M., Gillie, D.J., Schechter, M.S., Rubin, B.K. Am. J. Respir. Crit. Care Med. (2005) [Pubmed]
  27. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. Sonnenberg, A., Schwartz, J.S., Cutler, A.F., Vakil, N., Bloom, B.S. Arch. Intern. Med. (1998) [Pubmed]
  28. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Aubry, A., Chosidow, O., Caumes, E., Robert, J., Cambau, E. Arch. Intern. Med. (2002) [Pubmed]
  29. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. Ushiama, H., Echizen, H., Nachi, S., Ohnishi, A. Clin. Pharmacol. Ther. (2002) [Pubmed]
  30. Erythromycin, roxithromycin, and clarithromycin: use of slow-binding kinetics to compare their in vitro interaction with a bacterial ribosomal complex active in peptide bond formation. Dinos, G.P., Connell, S.R., Nierhaus, K.H., Kalpaxis, D.L. Mol. Pharmacol. (2003) [Pubmed]
  31. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Furuta, T., Shirai, N., Takashima, M., Xiao, F., Hanai, H., Sugimura, H., Ohashi, K., Ishizaki, T., Kaneko, E. Clin. Pharmacol. Ther. (2001) [Pubmed]
  32. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Pinto, A.G., Wang, Y.H., Chalasani, N., Skaar, T., Kolwankar, D., Gorski, J.C., Liangpunsakul, S., Hamman, M.A., Arefayene, M., Hall, S.D. Clin. Pharmacol. Ther. (2005) [Pubmed]
  33. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Desta, Z., Kerbusch, T., Flockhart, D.A. Clin. Pharmacol. Ther. (1999) [Pubmed]
  34. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Saito, M., Yasui-Furukori, N., Uno, T., Takahata, T., Sugawara, K., Munakata, A., Tateishi, T. British journal of clinical pharmacology. (2005) [Pubmed]
  35. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Hopkins, R.J. Gastroenterology (1997) [Pubmed]
  36. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Chaisson, R.E., Benson, C.A., Dube, M.P., Heifets, L.B., Korvick, J.A., Elkin, S., Smith, T., Craft, J.C., Sattler, F.R. Ann. Intern. Med. (1994) [Pubmed]
  37. Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance. Maeda, S., Yoshida, H., Ogura, K., Kanai, F., Shiratori, Y., Omata, M. Gut (1998) [Pubmed]
  38. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. Burman, W.J., Stone, B.L., Rietmeijer, C.A., Maslow, J., Cohn, D.L., Reves, R.R. AIDS (1998) [Pubmed]
  39. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Craig, W.A. Am. J. Med. (2004) [Pubmed]
 
WikiGenes - Universities